UK markets closed

Adocia SA (0QAI.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
3.3758-2.7400 (-44.80%)
At close: 06:45PM GMT

Adocia SA

115 Avenue Lacassagne
Lyon 69003
33 4 72 61 06 10

Full-time employees110

Key executives

NameTitlePayExercisedYear born
Dr. Gérard SoulaCo-Founder, Chairman, CEO, Pres and Interim Director of Bus. Devel. & Legal487.04kN/A1945
Mr. Olivier Soula M.B.A., Ph.D.Co-Founder, Deputy GM, VP, Director of R&D and Director344.04kN/A1970
Ms. Valérie DanaguezianCFO and Admin. & Financial DirectorN/AN/AN/A
Ms. Geraldine Favre SoulaHR Devel. DirectorN/AN/AN/A
Dr. Bertrand AlluisHead of the Analysis Department and Project Mang.N/AN/AN/A
Dr. David DuracherHead of the Pharmaceutical Devel. & Physical Chemistry Departments and Project Mang.N/AN/AN/A
Dr. Richard CharvetHead of Chemistry Department & Project Mang.N/AN/AN/A
Dr. Grégory MeiffrenHead of the Biology Department & Project Mang.N/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes bi-hormonal products, which include BioChaperone AsPram, which is a combination of rapid insulin aspart with pramlintide; and BioChaperone Glargine Liraglutidea, which is a fixed combination of insulin glargine with an analogue of the GLP-1 receptor. In addition, the company's preclinical pipeline includes multihormonal products for the treatment of obesity, including BioChaperone GluExe, which is a combination of glucagon and exenatide; PramExe, which is a combination of pramlintide and exenatide; and BioChaperone PramGluExe, which is a triple combination of pramlintide, glucagon and exenatide. It has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The company was incorporated in 2005 and is headquartered in Lyon, France.

Corporate governance

Adocia SA’s ISS governance QualityScore as of 1 November 2022 is 9. The pillar scores are Audit: 10; Board: 8; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.